Spironolactone, a mineralocorticoid receptor antagonist used for the treatment of heart failure, hypertension, edema, and primary hyperaldosteronism, is another pharmacological agent known to inhibit Panx1 (Good et al. 2018). The gene discussed is PANX1; the disease is heart failure.